ReviewMolecular pathology : MP2002
Angiogenesis in epithelian ovarian cancer.
Review in Molecular pathology : MP, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00868192 (Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma
Who cites it
63 citing papers in PubMed, 171 citations in OpenAlex.
- Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Trial
- Article
- Bacterial Extracellular Vesicles in Oncology: Molecular Mechanisms and Future Clinical Applications.Cancers · 2025Review
- The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model.BMC cancer · 2025Article
- Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer.Journal of ovarian research · 2024Article
- The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.Current oncology (Toronto, Ont.) · 2024Review
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.International journal of molecular sciences · 2024Review
- Role of Cancer Side Population Stem Cells in Ovarian Cancer Angiogenesis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.Therapeutic advances in medical oncology · 2024Review
- The long non-coding RNA NEAT1 promotes the progression of human ovarian cancer through targeting miR-214-3p and regulating angiogenesis.Journal of ovarian research · 2023Article
- Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine.Frontiers in pharmacology · 2023Review
- Differential Expression of HIF1A, EPAS1, and VEGF Genes in Benign and Malignant Ovarian Neoplasia.Cancers · 2022Article
- Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysis.Journal of ovarian research · 2022Article
- Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.Biomedicines · 2021Review
- Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy.Current oncology reports · 2021Review
- Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer.Biomolecules & therapeutics · 2021Article
- Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer.Clinical and translational medicine · 2021Article
- Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease.Cancer biology & therapy · 2021Review
- A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.Drug design, development and therapy · 2021Observational
- Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?Angiogenesis · 2020Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis, the development of new blood vessels from the existing vasculature, is an essential component of solid tumour growth and metastasis. Several angiogenic factors are expressed by many tumours, suggesting that tumours promote their own vascularisation by activating the host endothelium. This review will discuss various angiogenic stimulators and inhibitors in epithelian ovarian cancer (EOC), including vascular endothelial growth factor and platelet derived endothelial cell growth factor/thymidine phosphorylase. The analysis of tumour vascularisation by microvessel density will also be discussed and the relevance of these markers of angiogenesis in the prognosis of EOC will be assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.